期刊
LEUKEMIA
卷 23, 期 9, 页码 1628-1633出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2009.156
关键词
chronic myeloid leukemia; dasatinib; BCR-ABL; treatment outcome; progression-free survival
资金
- Bristol-Myers Squibb
- German Jose-Carreras Foundation [DJCLS H 03/01]
Dasatinib is a highly potent BCR-ABL inhibitor that has shown durable efficacy in patients with chronic phase (CP) chronic myeloid leukemia (CML) after resistance, suboptimal response, or intolerance to prior imatinib. In patients with CML, BCR-ABL transcript measurement is the most sensitive method for assessing minimal residual disease. Here, molecular responses were analyzed in 1067 patients with CML-CP treated with dasatinib during phase II/III trials. After 3, 6, 12, and 24 months of follow-up, a major molecular response (MMR) was achieved by 12, 22, 35, and 40% of patients, respectively. The 24-month MMR rate was 34% in patients with resistance or suboptimal response to imatinib (n = 829) and 63% in imatinib-intolerant patients (n = 238). Among patients who had achieved a complete cytogenetic response (CCyR), 72% also achieved MMR. Responses with dasatinib 100mg once daily were similar to other doses. In landmark analyses, 24-month progression-free survival was higher in patients who had achieved MMR or CCyR at 12 months than in those without MMR or CCyR at 12 months. MMR at 12 months was associated with a longer duration of CCyR. Overall, this analysis shows that dasatinib treatment results in high MMR rates in patients with CML-CP after imatinib failure. Leukemia (2009) 23, 1628-1633; doi:10.1038/leu.2009.156; published online 30 July 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据